AVIR vs NBIX · $353.7M cap vs P/E 45, rev $1.77B
Atea Pharmaceuticals Inc (AVIR) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Atea Pharmaceuticals Inc (AVIR) is a biotechnology company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
AVIR does not have a complete income-statement cache yet.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
AVIR currently screens at market cap $353.7M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the AVIR and NBIX stock pages for the full models.
Not investment advice.